



Best Available Copy

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/381,747	09/22/1999	MAR TORMO	UTSC:550---/IPAR	4363

7590

11/15/2005

DAVID L PARKER
ARNOLD WHITE & DURKEE
PO BOX 4433
HOUSTON, TX 77210

EXAMINER

CHONG, KIMBERLY

ART UNIT


PAPER NUMBER

1635

DATE MAILED: 11/15/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary



Application No.

09/381,747

Applicant(s)

TORMO ET AL.

Examiner

Kimberly Chong

Art Unit

1635

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE ____ MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 19 August 2005.
- 2a) ☐ This action is FINAL. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-20 and 22-49 is/are pending in the application.
- 4a) Of the above claim(s) ____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) ____ is/are allowed.
- 6) ☒ Claim(s) 1-20 and 22-49 is/are rejected.
- 7) ☐ Claim(s) ____ is/are objected to.
- 8) ☐ Claim(s) ____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on ____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
- Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
- Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
- ☐ Certified copies of the priority documents have been received.
 - ☐ Certified copies of the priority documents have been received in Application No. ____.
 - ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- 1) ☒ Notice of References Cited (PTO-892)
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) ☐ Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)
Paper No(s)/Mail Date ____
- 4) ☐ Interview Summary (PTO-413)
Paper No(s)/Mail Date. ____
- 5) ☐ Notice of Informal Patent Application (PTO-152)
- 6) ☐ Other: ____

DETAILED ACTION

Status of Application/Amendment/Claims

Applicant's response filed 08/19/2005 has been considered. Rejections and/or objections not reiterated from the previous office action mailed 05/17/2005 are hereby withdrawn. The following rejections and/or objections are either newly applied or are reiterated and are the only rejections and/or objections presently applied to the instant application.

The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action.

With entry of the amendment filed on 08/19/2005, claims 1-20 and 22-49 are pending in the application.

Double Patenting

The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. See *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent is shown to be commonly owned with this application. See 37 CFR 1.130(b).

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

Art Unit: 1635

Claims 1-20 and 22-38 are provisionally rejected under the judicially created doctrine of double patenting over claims 58-65, 72-76, 79-89, 91 and 92 of copending Application No. 08/726,211. Although the conflicting claims are not identical, they are not patentably distinct from each other because the instant claims and the claims of the copending application are drawn to patentably indistinguishable subject matter

The instant claims are drawn to a composition comprising a P-ethoxy polynucleotide that hybridizes to a Bcl-2-encoding polynucleotide to form a neutrally-charged polynucleotide/lipid association wherein the polynucleotide is between 8-50 bases, the P-ethoxy is complementary to the translation initiation site of Bcl-2 mRNA, the polynucleotide is an oligonucleotide comprising SEQ ID NO.1, or wherein said neutral lipid is a phosphatidycholine, phosphatidylglycerol, phosphatidylethanolamine and further the composition comprises an expression cassette that encodes a P-ethoxy polynucleotide. The subject matter of the instant claims is further drawn to a method of inhibiting a Bcl-2 associated disease in a cancer comprising administering a polynucleotide/lipid association that hybridizes to a Bcl-2 encoding polynucleotide wherein the association comprising an oligonucleotide 8-50 bases, the association is delivered in a volume of 0.50-10.0 ml per dose, the association is delivered in an amount from about 5-30 mg per m² and the antisense is from 8-50 bases and is a P-ethoxy polynucleotide.

Claims 58-65, 72-76, 79-89, 91 and 92 of copending Application No. 08/726,211 are drawn to a composition comprising a polynucleotide that hybridizes to a Bcl-2-encoding polynucleotide to form a neutrally-charged polynucleotide/lipid association wherein the polynucleotide is between 8-50 bases, the polynucleotide is complementary to the translation initiation site of Bcl-2 mRNA, the polynucleotide is a P-ethoxy oligonucleotide, the

Art Unit: 1635

polynucleotide is an oligonucleotide comprising SEQ ID NO.1, or wherein said neutral lipid is a phosphatidycholine, phosphatidylglycerol, phosphatidylethanolamine and further the composition comprises an expression cassette that encodes a P-ethoxy polynucleotide.

The method of the instant claims are encompassed in the methods of claims 11-15, 18-20, 22-25, 28-30, 44-46, 58-65, 72-76, 79-89, 91 and 92 of copending Application No. 08/726,211 because disease cells having a t(14;18) translocation are cancer cells as evidence by Korsmeyer et al. (Cancer Biology 1993) who states a t(14;18) translocation constitutes the most common chromosomal translocation in human lymphoid malignancies (see page 328).

This is a provisional double patenting rejection since the conflicting claims have not yet been patented.

Claims 39-49 are provisionally rejected under the judicially created doctrine of double patenting over claims 11-15, 18-20, 22-25, 28-30 and 44,46 of copending Application No. 08/726,211. Although the conflicting claims are not identical, they are not patentably distinct from each other because the instant claims and the claims of the copending application are drawn to patentably indistinguishable subject matter

The subject matter of the instant claims are drawn to a method of inhibiting a Bcl-2 associated disease in a cell that expresses both Bcl-2 and Bax and comprises administering a polynucleotide/lipid association that hybridizes to a Bcl-2 encoding polynucleotide wherein the association comprising an oligonucleotide 8-50 bases, the association is delivered in a volume of 0.50-10.0 ml per dose, the association is delivered in an amount from about 5-30 mg per m² and the antisense is from 8-50 bases.

The subject matter of the claims 11-15, 18-20, 22-25, 28-30, 44-46 of copending Application No. 08/726,211 are drawn to a method of inhibiting a Bcl-2 associated disease in a cell, wherein the cells have a t(14;18) translocation and wherein the method comprises administering a polynucleotide/lipid association that hybridizes to a Bcl-2 encoding polynucleotide wherein the association comprising an oligonucleotide 8-50 bases, the association is delivered in a volume of 0.50-10.0 ml per dose, the association is delivered in an amount from about 5-30 mg per m² and the antisense is from 8-50 bases.

The method of the instant claims are encompassed in the methods of claims 11-15, 18-20, 22-25, 28-30, 44-46 of copending Application No. 08/726,211 because as evidenced by Korsmeyer et al. (Cancer Biology 1993) a cell comprises both Bcl-2 and Bax which are essential in determining the survival or death of cells following an apoptotic stimulus (see Abstract and page 331).

Response to Applicant's Arguments

Correction of Filing Receipt

It is noted that Applicants are requesting correcting of filing receipt. The request has been forwarded to the appropriate department.

Claim Rejections - 35 USC § 112

The rejection of claims 10-20, 25 and 39-49 under 35 U.S.C. 112, first paragraph enablement, in the Office Action mailed 02/01/2001 has been withdrawn in response to Applicant's arguments.

The rejection of claims 1-9, 21-24 and 26-38 as being obvious under 35 U.S.C. 103(a) over Evan (WO 93/20200) or Reed (WO 95/08350) or Green et al. (U.S. Patent No. 5, 583,034) each in view of Lopez-Berestein et al. (U.S. Patent No. 5, 855,911) has been overcome due to Applicant's statement of common obligation of assignment between Lopez-Berestein et al. (U.S. Patent No. 5, 855,911) and the instant application.

MPEP 706.02(l)(2) II states "...if the applicant(s) or an attorney or agent of record makes a statement to the effect that the application and the reference were, at the time the invention was made, owned by, or subject to an obligation of assignment, the same person.", this statement is sufficient evidence to establish common ownership at the time the invention was made.

Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Kimberly Chong whose telephone number is 571-272-3111. The examiner can normally be reached Monday thru Friday between 7-4 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Andrew Wang can be reached at 571-272-0811. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.


Patent applicants with problems or questions regarding electronic images that can be viewed in the Patent Application Information Retrieval system (PAIR) can now contact the USPTO's Patent Electronic Business Center (Patent EBC) for assistance. Representatives are available to answer your questions daily from 6 am to midnight (EST). The toll free number is

Art Unit: 1635

(866) 217-9197. When calling please have your application serial or patent number, the type of document you are having an image problem with, the number of pages and the specific nature of the problem. The Patent Electronic Business Center will notify applicants of the resolution of the problem within 5-7 business days. Applicants can also check PAIR to confirm that the problem has been corrected. The USPTO's Patent Electronic Business Center is a complete service center supporting all patent business on the Internet. The USPTO's PAIR system provides Internet-based access to patent application status and history information. It also enables applicants to view the scanned images of their own application file folder(s) as well as general patent information available to the public. For more information about the PAIR system, see <http://pair-direct.uspto.gov>.

For all other customer support, please call the USPTO Call Center (UCC) at 800-786-9199.

Kimberly Chong
Examiner
Art Unit 1635


SEAN MCGARRY
PRIMARY EXAMINER
1635

Notice of References Cited	Application/Control No. 09/381,747	Applicant(s)/Patent Under Reexamination TORMO ET AL.	
	Examiner Kimberly Chong	Art Unit 1635	Page 1 of 1

U.S. PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	Classification
	A	US-			
	B	US-			
	C	US-			
	D	US-			
	E	US-			
	F	US-			
	G	US-			
	H	US-			
	I	US-			
	J	US-			
	K	US-			
	L	US-			
	M	US-			

FOREIGN PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	Classification
	N					
	O					
	P					
	Q					
	R					
	S					
	T					

NON-PATENT DOCUMENTS

*		Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)
	U	Korsmeyer et al. Bcl-2?Bax: a rheostat that regulates an anti-oxidant pathway and cell death. Cancer Biology, 1993, Vol. 4: 327-332. Academic Press Ltd.
	V	
	W	
	X	

*A copy of this reference is not being furnished with this Office action. (See MPEP § 707.05(a).)
Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.

Bcl-2/Bax: a rheostat that regulates an anti-oxidant pathway and cell death

Stanley J. Korsmeyer, John R. Shutter, Deborah J. Veis, Diane E. Merry and Zoltan N. Ottvai

The maintenance of homeostasis in normal tissues reflects a balance between cell proliferation and cell death. The importance of both positive and negative regulators of cell growth has been well documented in neoplasia. Bcl-2 argues for the existence of a new category of oncogenes, regulators of cell death. The bcl-2 gene was identified at the chromosomal breakpoint of t(14;18) bearing B cell lymphomas. Bcl-2 has proved to be unique among protooncogenes in blocking programmed cell death rather than promoting proliferation. In adults, bcl-2 is topographically restricted to progenitor cells and longlived cells but is much more widespread in the developing embryo. Transgenic mice that overexpress bcl-2 in the B cell lineage demonstrate extended cell survival, and progress to high grade lymphomas. Bcl-2 has been localized to mitochondria, endoplasmic reticulum and nuclear membranes, also the sites of reactive oxygen species generation. Bcl-2 does not appear to influence the generation of oxygen free radicals but does prevent oxidative damage to cellular constituents including lipid membranes. Bcl-2 deficient mice complete embryonic development and display relatively normal haematopoietic differentiation but undergo fulminant lymphoid apoptosis of thymus and spleen. Moreover, they demonstrate two potentially oxidation related pathologies: polycystic kidney disease and hair hypopigmentation. A family of bcl-2 related genes is emerging that includes Bax, a conserved homolog that heterodimerizes in vivo with bcl-2. A pre-set ratio of Bcl-2/Bax appears to determine the survival or death of cells following an apoptotic stimulus.

Key words: apoptosis / cell death / Bcl-2 / oncogene / free radical

Bcl-2 initiates a new category of oncogenes: regulators of cell death

Malignancies usually possess aberrations in more than a single pathway.¹ Either increased proliferation

or decreased death might result in an expansion of cell numbers (Figure 1). To date, most of our knowledge concerning oncogenic events has concentrated upon mechanisms of increased growth and proliferation. Studies of bcl-2 emphasize the existence of multiple pathways in the generation of neoplasia (Figure 1). The increased cell number in neoplastic tissue can be viewed as a violation of normal homeostasis. The maintenance of homeostasis in normal tissue, in many respects, reflects a simple balanced equation of input (cellular proliferation and renewal) versus output (cell death). The maintenance of remarkably invariant cell numbers must reflect tightly regulated death pathways as well as controlled proliferation (Figure 1).

Programmed cell death represents a cell autonomous suicide pathway that helps restrict cell numbers. The well defined loss of specific cells is crucial during embryonic development as part of organogenesis.² In mature tissues, genetically programmed demise regulates the volume of cells. Andrew Wyllie identified a morphologically distinct and highly ritualistic cell death entitled apoptosis.³ Cells dying by apoptosis display marked plasma membrane blebbing, volume contraction, nuclear condensation and the activation of an endonuclease that cleaves




Figure 1. Schematic representation of normal tissue homeostasis with balanced input and output reactions. Alternative roads to neoplasia are depicted as either increased proliferation (In) or decreased death (Out).

From the [Howard Hughes Medical Institute] at [Washington University School of Medicine], 660 South Euclid Avenue, [St Louis, MO 63110] USA
©1993 Academic Press Ltd
1044-579X/93/060327 + 06\$8.00/0

DNA into nucleosomal length fragments. Defining the precise genes and biochemical events that regulate this death program holds the promise for novel therapeutic approaches.

The t(14;18) breakpoint of follicular lymphoma reveals the *bcl-2* gene

The t(14;18)(q32;q21) constitutes the most common chromosomal translocation in human lymphoid malignancies. Approximately 85% of follicular and 20% of diffuse B cell lymphomas possess this translocation.^{4,5} As a disease, follicular lymphoma provided many clues concerning the ultimate function of the *bcl-2* molecule. Follicular lymphoma often presents as a low-grade malignancy comprised of small resting IgM/IgD B cells. Over time conversion to an aggressive high grade lymphoma with a diffuse large cell architecture frequently occurs in these patients.⁶ The location of the immunoglobulin (Ig) heavy chain locus at 14q32 and the B cell phenotype of this lymphoma provided the rationale for cloning the chromosomal breakpoint. Aberrant Ig heavy chain gene rearrangements in t(14;18) lymphomas proved to be the chromosomal breakpoint and delivered a candidate oncogene, *bcl-2*, at 18q21.⁷⁻⁹

Bcl-2 represses programmed cell death

Whether the newly discovered genes found at chromosomal breakpoints could be shown to be transforming remained a major question. To assess whether *bcl-2* might be involved in a growth factor pathway, vectors overproducing *bcl-2* were introduced into a variety of interleukin (IL) dependent cell lines. Such lines were examined to determine if *bcl-2* would spare the need for a specific ligand/receptor interaction. However, no long-term growth factor independent cell lines emerged following overexpression of *bcl-2* and a more novel effect was noted that helped define a physiologic role for *bcl-2*. *Bcl-2* conferred a death sparing effect to certain haematopoietic cell lines following growth factor withdrawal.¹⁰⁻¹² This was noted in the IL-3 dependent early haematopoietic cell lines although the effect was not restricted to the IL-3/IL-3 receptor signal transduction pathway in that GM-CSF and IL-4 deprived cells displayed a similar response. Yet, *bcl-2* enhanced cell survival was not universal as IL-2

dependent T cell lines showed no consistent effect upon factor withdrawal. Even these early studies indicated a selectivity to *bcl-2*'s interference with cell death.

Bcl-2 protein distribution in adult and embryonic tissues

Bcl-2 protein displays a very restricted topographic distribution within mature tissues characterized by apoptotic cell death.¹³ One of the most dramatic examples is provided by 2° germinal centers. Immunohistochemical assessment revealed that the follicular mantle, composed of long-lived recirculating IgM/IgD B cells, possessed abundant *bcl-2*.^{13,14} *Bcl-2* protein was absent from the dark zone of proliferating centroblasts and from the portion of the light zone where centrocytes are dying by apoptosis. Yet, *bcl-2* expression returns in B cells in the more apical portion of the light zone where B cells are selected for survival.

An initial survey of tissues argued strongly that *bcl-2* had roles beyond B cells. The thymus has distinct cortical and medullary regions that possess thymocytes at serial stages of maturation. *Bcl-2* was present in the surviving CD4⁺ or CD8⁺ mature thymocytes of the medulla. The majority of CD4⁺ 8⁺ immature cortical thymocytes, most of which die by apoptosis, displayed no *bcl-2*.¹³⁻¹⁵ All haematopoietic lineages that derive from a renewing stem cell also display *bcl-2*. While present in the precursor cells it is absent in their most differentiated and terminal progeny. Another category of tissues that express *bcl-2* is glandular epithelium that undergoes hyperplasia or involution, usually in response to hormonal stimuli or growth factors. In organized epithelium, *bcl-2* is restricted to stem cell and proliferation zones. *Bcl-2* is present in the lower crypts of the intestine and the basal layer of epidermis shows it. *Bcl-2* may be required to save the progenitor and long-lived cells in such lineages.

Within the embryo, *bcl-2* is expressed in most organs examined (D.J. Veis, S.J. Korsmeyer, submitted). *Bcl-2* is expressed in cells within the digital zones of the developing limb bud, but not in the interdigital zones of cell death. *Bcl-2* is especially prominent in the nervous system, both in the proliferating ventricular layer and in post-mitotic populations of the cortical plate, cerebellum, hippocampus, and spinal cord (D.E. Merry et al, submitted). *Bcl-2* expression does not always mirror

recognized patterns of cell death. Bcl-2 expression in the CNS declines with aging. In the regeneration competent peripheral nervous system, neurons and supporting cells of sympathetic and sensory ganglia retain substantial bcl-2 protein throughout life. Developmental patterns of bcl-2 expression suggest that the susceptibility to cell death is much more widespread in the embryo than appreciated, or that bcl-2 has a role beyond the regulation of cell death.

Gain of function transgenic mice satisfy a molecular Koch's postulate

A stringent test of a gene's oncogenic capacity is to place it into the germline of mice to observe its effects during the development of an entire organism. Transgenic mice bearing a *bcl-2* Ig minigene initially displayed a polyclonal follicular lymphoproliferation that selectively expanded a small resting IgM/IgD B cell population. Cell cycle analysis confirmed that ~97% of the expanded B cells reside in G0/G1. These recirculating B cells accumulate because of an extended survival rather than an increased proliferation.^{16,17} Over time these transgenics progress from indolent follicular hyperplasia to diffuse large cell immunoblastic lymphoma.¹⁸ A long latency period and progression from polyclonal hyperplasia to monoclonal high-grade malignancy is an indictment of secondary genetic abnormalities. Approximately half of the high grade tumours possess a *c-myc* translocation involving an Ig H chain locus. These tumour cells have complemented an inherent survival advantage (*bcl-2*) with a gene that promotes proliferation (*myc*). When *bcl-2* transgenic mice were mated to *myc* transgenic mice a rapidly emerging undifferentiated haematopoietic leukaemia occurred providing further testimony for the potent synergy of this particular oncogene combination.¹⁹ In addition to promoting cell cycle progression *myc* has been shown to promote apoptosis.²⁰ Thus, the overexpression of *myc* may specifically benefit from bcl-2's ability to block apoptosis. Finally, the Bcl-2-Ig mice document the prospective importance of the t(14;18) in setting the stage for tumour progression and lymphomagenesis.

To assess the role of bcl-2 in T cell development transgenic mice were generated in which bcl-2 was redirected to the immature T cells in the cortex of the thymus.²¹ The idea was to place this particular antidote to programmed death proximal to positive and negative selection. A separate transgenic model also overexpressed bcl-2 in the thymus and displayed

similar effects.²² The introduction of bcl-2 into the normally vulnerable cortical thymocytes protected them from a wide variety of apoptotic stimuli including glucocorticoids, radiation and anti-CD3 treatment. Moreover, bcl-2 altered T cell maturation increasing a distinct subpopulation of cells that had intermediate levels of TCR, so called TCR/CD3^{Med} cells and promoting maturation along a CD8 pathway. Despite these profound alterations by bcl-2, negative selection still occurred to eliminate self reactive T cells. One interpretation of these transgenic models is that the thymus has multiple death pathways.

Bcl-2's subcellular localization may provide a clue to its function

Bcl-2 has a C-terminal hydrophobic region that functions as a signal-anchor sequence responsible for the integral membrane position of the 25 kDa Bcl-2 α product.²³ *In vitro* targeting studies indicate that while it can target microsomes, it selectively integrates into the outer membrane of mitochondria with its NH₂-terminus facing the cytosol. In addition bcl-2 has been localized to other membranes including endoplasmic reticulum and nuclear membrane.²⁴⁻²⁶ The majority of bcl-2 within lymphocytes localizes to mitochondria providing a vantage point from which to address bcl-2's potential metabolic role in opposing cell death.

Bcl-2 regulates an anti-oxidant pathway

Bcl-2's ability to block γ -irradiation-induced cell death^{21,22} is notable in that ionizing radiation produces hydroxyl radicals (OH \cdot) in aqueous solution by radiolytic attack on H₂O.²⁷ Bcl-2 is localized to the intracellular sites of oxygen free radical generation including mitochondria, endoplasmic reticulum and nuclear membranes. Many of the effects of oxygen free radicals including DNA strand breaks and membrane blebbing match the hallmark features of apoptosis, prompting an examination of bcl-2's ability to counter other oxidative cell deaths. Bcl-2 protected cells from the lethal effect of H₂O₂ in a dose dependent manner, a death that resembles apoptosis morphologically. Bcl-2 also interfered with cell death induced by menadione, a quinone compound which undergoes redox cycles intracellularly to generate superoxide, O₂⁻.²⁸ Importantly bcl-2

potential. Changes in the metabolism of peroxides and free radicals could impact both melanin synthesis and cellular survival.

Bcl-2/bax: a cell autonomous rheostat controls cell death

Since bcl-2 lacked any conserved functional motifs it was possible that it comprised a member of a multicomponent complex. Immunoprecipitation revealed that bcl-2 heterodimerizes *in vivo* with a 21 kDa partner, bax (bcl-2 associated X protein).³⁴ Of note, was the unanticipated finding that bax shared homology with bcl-2 clustered within two highly conserved domains I and II. These motifs define a family including *bcl-x*, *mcl-1* and *A1*. These genes are likely to be sequential members in a single death pathway or regulators of parallel pathways. Given the heterodimerization of family members, it was possible that *bax* worked in concert with *bcl-2* to repress death or that this represented 'hand to hand' combat in which *bax* promoted death while *bcl-2* opposed it. Overexpression studies indicated that excess bax countered bcl-2 and accelerated apoptotic cell death, but only following a death signal.³⁴ Of note, the bcl-2/bax association exists in cells prior to a death stimulus and is not markedly altered in the early death process. When bcl-2 is in excess bcl-2 homodimers dominate and cells are protected. When bax is in excess bax homodimers dominate and cells are susceptible to apoptosis (Figure 3). A number of biologic systems indicate that cells vary during development in their inherent sensitivity or resistance to a given death stimulus. The ratio of bcl-2/bax represents a cell autonomous rheostat that pre-determines a cell's life or death response to an apoptotic stimulus. As a testable model, perhaps such protein/protein interactions

could serve to focus as well as regulate an anti-oxidant pathway at the selective sites of ROS generation.

References

1. Land H, Parada LF, Weinberg RA (1983) Tumorigenic conversion of primary embryo fibroblasts requires at least two cooperating oncogenes. *Nature* 304:596-602
2. Glucksmann A (1951) Cell deaths in normal vertebrate ontogeny. *Biol Rev* 26:59
3. Wyllie AH (1987) Apoptosis: cell death in tissue regulation. *J Pathol* 153:313-316
4. Fukuhara S, Rowley JD, Varrakojis D, Golomb HM (1979) Chromosome abnormalities in poorly differentiated lymphocytic lymphoma. *Cancer Res* 39:3119-3128
5. Yunis JJ, Frizzera G, Oken MM, McKenna J, Theologides A, Arnesen M (1987) Multiple recurrent genomic defects in follicular lymphoma. *N Engl J Med* 316:79-84
6. Horning SJ, Rosenberg SA (1984) The natural history of initially untreated low-grade non-Hodgkin's lymphomas. *N Engl J Med* 311:1471-1475
7. Tsujimoto Y, Gorham J, Cossman J, Jaffe E, Croce CM (1985) The t(14;18) chromosome translocations involved in B-cell neoplasms result from mistakes in VDJ joining. *Science* 229:1390-1393
8. Bakhshi A, Jensen JP, Goldman P, Wright JJ, McBride OW, Epstein AL, Korsmeyer SJ (1985) Cloning the chromosomal breakpoint of t(14;18) human lymphomas: clustering around J_H on chromosome 14 and near a transcriptional unit on 18. *Cell* 41:899-906
9. Cleary ML, Sklar J (1985) Nucleotide sequence of a t(14;18) chromosomal breakpoint in follicular lymphoma and demonstration of a breakpoint cluster region near a transcriptionally active locus on chromosome 18. *Proc Natl Acad Sci USA* 82:7439-7443
10. Vaux DL, Cory S, Adams JM (1988) Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. *Nature* 335:440-442
11. Hockenbery D, Nunez G, Millman C, Schreiber RD, Korsmeyer SJ (1990) Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. *Nature* 348:334-336
12. Nunez G, London L, Hockenbery D, Alexander M, McKearn J, Korsmeyer SJ (1990) Deregulated Bcl-2 gene expression selectively prolongs survival of growth factor-deprived hemopoietic cell lines. *J Immunol* 144:3602-3610
13. Hockenbery D, Zutter M, Hickey W, Nahm M, Korsmeyer SJ (1991) Bcl-2 protein is topographically restricted in tissues characterized by apoptotic cell death. *Proc Natl Acad Sci USA* 88:6961-6965
14. Pezzella F, Tse AG, Cordell JL, Pulford KAF, Guter KC, Mason RY (1990) Expression of the Bcl-2 oncogene protein is not specific for the 14;18 chromosome translocation. *Am J Path* 137:225-232
15. Veis DJ, Sentman CL, Bach EA, Korsmeyer SJ (1993) Expression of the Bcl-2 protein in murine and human thymocytes and in peripheral T lymphocytes. *J Immunol* 151:2546-2554
16. McDonnell TJ, Deane N, Platt FM, Nunez G, Jaeger U, McKearn JP, Korsmeyer SJ (1989) Bcl-2-immunoglobulin transgenic mice demonstrate extended B cell survival and follicular lymphoproliferation. *Cell* 57:79-88
17. McDonnell TJ, Nunez G, Platt FM, Hockenbery D, London L, McKearn JP, Korsmeyer SJ (1990) Deregulated Bcl-2-immunoglobulin transgene expands a resting but




Figure 3. A pre-set rheostat of the ratio of bcl-2/bax determines the life or death response of a cell following a programmed cell death (PCD) signal.

- responsive immunoglobulin M and D-expressing B-cell population. *Mol Cell Biol* 10:1901-1907
18. McDonnell TJ, Korsmeyer SJ (1991) Progression from lymphoid hyperplasia to high-grade malignant lymphoma in mice transgenic for the t(14;18). *Nature* 349:254-257
 19. Strasser A, Harris AW, Bath ML, Cory S (1990) Novel primitive lymphoid tumours induced in transgenic mice by cooperation between myc and bcl-2. *Nature* 348:331-333
 20. Evan GI, Wyllie AH, Gilbert CS, Littlewood TD, Land H, Brooks M, Waters CM, Penn LZ, Hancock DC (1992) Induction of apoptosis in fibroblasts by c-myc protein. *Cell* 69:119-128
 21. Sentman CL, Shutter JR, Hockenbery D, Kanagawa O, Korsmeyer SJ (1991) Bcl-2 inhibits multiple forms of apoptosis but not negative selection in thymocytes. *Cell* 67:879-888
 22. Strasser A, Harris AW, Cory S (1991) Bcl-2 transgene inhibits T cell death and perturbs thymic self-censorship. *Cell* 67:889-899
 23. Nguyen M, Millar DG, Wee Yong V, Korsmeyer SJ, Shore GC (1993) Targeting of Bcl-2 to the mitochondrial outer membrane by a COOH-terminal signal-anchor sequence. *J Biol Chem*, in press
 24. Chen-Levy Z, Cleary ML (1990) Membrane topology of the Bcl-2 proto-oncogenic protein demonstrated *in vivo*. *J Biol Chem* 265:4929-4933
 25. Jacobson MD, Burnett JF, King MD, Miyashita T, Reed JC, Raff MC (1993) Bcl-2 blocks apoptosis in cells lacking mitochondrial DNA. *Nature* 361:365-369
 26. Monaghan P, Robertson D, Amos TAS, Dyer MJS, Mason DY, Graves MF (1992) Ultrastructural localization of Bcl-2 protein. *J Histochem Cytochem* 40:1819-1825
 27. Blok J, Lohman H (1986) Mechanisms of DNA damage and repair (Simic MG, ed), pp 75-87. Plenum Press, New York
 28. Hockenbery DM, Oltvai ZN, Yin X-M, Millman CL, Korsmeyer SJ (1993) Bcl-2 functions in an anti-oxidant pathway to prevent apoptosis. *Cell* 75:241-251
 29. Mansour S, Thomas KR, Capecchi MR (1988) Disruption of the proto-oncogene int-2 in mouse embryo-derived stem cells: a general strategy for targeting mutations to non-selectable genes. *Nature* 336:348-352
 30. Veis DJ, Sorenson CM, Shutter JR, Korsmeyer SJ (1993) Bcl-2 deficient mice demonstrate fulminant lymphoid apoptosis, polycystic kidneys and hypopigmented hair. *Cell* 75:229-240
 31. Boise LH, Gonzalez-Garcia M, Postems CE, Ding L, Lindsten T, Turka LA, Mao X, Nunez G, Thompson CB (1993) Bcl-x, a Bcl-2 related gene that functions as a dominant regulator of apoptotic cell death. *Cell* 74:597-608
 32. Kozopas KM, Yang T, Buchan HL, Zhou P, Craig RW (1993) MCL-1, a gene expressed in programmed myeloid cell differentiation, has sequence similarity to Bcl-2. *Proc Natl Acad Sci USA* 90:3516-3520
 33. Lin EY, Orlofsky A, Berger M-S, Prystowsky MB (1993) Characterization of A1, a novel hemopoietic-specific early-response gene with sequence similarity to Bcl-2. *J Immunol* 151:1979-1988
 34. Oltvai Z, Millman C, Korsmeyer SJ (1993) Bcl-2 heterodimerizes *in vivo* with a conserved homolog, Bax, that accelerates programmed cell death. *Cell* 74:609-619

Organization

IC1600

Bldg./Room

REMSEN

U. S. DEPARTMENT OF COMMERCE
COMMISSIONER FOR PATENTS
P.O. BOX 1450

ALEXANDRIA, VA 22313-1450

IF UNDELIVERABLE RETURN IN TEN DAYS

OFFICIAL BUSINESS

AN EQUAL OPPORTUNITY EMPLOYER



UNITED STATES POSTAGE
02 1A
0004204479
MAILED FROM ZIP

RETURN TO SENDER

UNDELIVERABLE AS ADDRESSED

RETURN TO SENDER



**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.